ZPL-389

Novartis has registered a first-in-human trial of DCY636, an investigational drug whose molecular target has not been publicly disclosed, in adults with moderate to severe atopic dermatitis. The DCY636 clinical trial, registered on ClinicalTrials.gov as NCT07604324, was posted on May 22, 2026, with a planned start date of May 25, 2026, and no sponsor identity has been made available in the registry record or any publicly accessible source at the time of reporting. The trial is structured in two sequential parts enrolling a total of 63 participants. Part 1 is a single ascending dose study in healthy adults across six dose cohorts, while Part 2 evaluates multiple doses in adults with moderate-to-severe AD inadequately controlled by topical therapies. Both portions are randomised, double-blind, placebo-controlled studies. Primary endpoints focus on safety and tolerability, including adverse events, laboratory changes, electrocardiograms, and vital signs, while secondary endpoints include pharmacokinetics and anti-drug antibody assessment. Although Novartis has not disclosed DCY636’s target or modality, several features of the protocol are consistent with a long-acting biologic. The study includes dedicated immunogenicity monitoring, and protocol-defined washout periods imply a terminal half-life of roughly 40 days, more characteristic of an antibody-based therapeutic than a small molecule. No route of administration or mechanism of action has been disclosed publicly. The trial is structured in two sequential parts enrolling a total of 63 participants. Part 1 is a single ascending dose study in healthy adults across six dose cohorts, while Part 2 evaluates multiple doses in adults with moderate-to-severe AD inadequately controlled by topical therapies. Both portions are randomized, double-blind, placebo-controlled studies. Primary endpoints focus on safety and tolerability, including adverse events, laboratory changes, electrocardiograms, and vital signs, while secondary endpoints include pharmacokinetics and anti-drug antibody assessment. Although Novartis has not disclosed DCY636’s target or modality, several features of the protocol are consistent with a long-acting biologic. The study includes dedicated immunogenicity monitoring, and protocol-defined washout periods imply a terminal half-life of roughly 40 days, more characteristic of an antibody-based therapeutic than a small molecule. No route of administration or mechanism of action has been disclosed publicly. The program expands Novartis’s broader immunology and dermatology pipeline beyond its established IL-17 franchise led by Cosentyx (secukinumab). While Novartis holds a major commercial position in psoriasis, it has yet to establish a leading presence in AD, a market currently dominated by Dupixent (dupilumab) and increasingly contested by newer biologics and JAK inhibitors. The company has previously pursued AD programs including the IL-17C antibody MOR106, licensed from Galapagos and MorphoSys, and the H4 receptor antagonist ZPL389 acquired through its purchase of Ziarco Group. The moderate-to-severe AD population enrolled in the study reflects a commercially important segment of the disease market. Eligibility criteria require inadequate disease control with topical therapies alongside established severity thresholds including EASI, IGA, body surface area involvement, and pruritus scoring. These measures are standard in contemporary AD development programs and suggest the study was designed to support future efficacy-focused expansion if safety and pharmacokinetic data prove favorable. The absence of target disclosure leaves open whether DCY636 is directed at a validated inflammatory pathway already established in AD — such as IL-13, IL-31, TSLP, or OX40 signaling — or represents a novel immunologic mechanism. The compound naming convention also does not align with commonly used Novartis internal nomenclature, raising the possibility that the asset may have originated externally through licensing or acquisition, although no public transaction linked to DCY636 has been identified. Primary completion of the Phase I study is projected for January 2028. Initial safety, pharmacokinetic, and immunogenicity data will determine whether Novartis advances the asset into mid-stage efficacy testing and provide the first indication of how the company intends to position DCY636 within the increasingly competitive AD treatment landscape. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.